91895-51-1Relevant articles and documents
HMPA mediated one pot synthesis of 1-alkyl/aryl-4-dimethylamino[1,2,4]triazalo[4,3-a]quinoxalines
Krishnan,Chowdary,Dubey
, p. 329 - 333 (2007/10/03)
o-Phenylenediamine 1 is condensed with oxalic acid using Phillips' procedure to obtain quinoxaline-2, 3-dione 2. The latter on treatment with hydrazine hydrate gives the known 2-hydrazinoquinoxalin -3-one 3. Reaction of 3 with various acid chlorides (which were obtained from the corresponding carboxylic acids by reaction with thionyl chloride in the presence of catalytic amount of dimethyl formamide) in HMPA medium at 220°C in one pot reaction yield the corresponding 1-substituted-4-dimethylamino[1, 2, 4]triazolo[4, 3-a]quinoxalines 4. This reaction has been shown to proceed through the intermediacy of 2-(N-acyl/aryl hydrazinoquinoxalin -3-one 5 and 1-substituted-4-oxo-[1, 2, 4] triazolo[4, 3-a]quinoxalines 6. An interesting observation here has been that 5 can be cyclised to 6 at a considerably lower temperature of 100°C than the requisite 220°C using catalytic amount of HCl.
Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
-
, (2008/06/13)
A series of novel [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives wherein the amine group is optionally substituted with lower alkyl, phenylalkyl having up to three carbon atoms in the alkyl moiety or alkanoyl having from two to five carbon atoms, or the amine group alternatively completes a piperazino ring, the quinoxaline ring is optionally substituted with fluorine, chlorine, bromine or methoxy, and the triazolo ring is optionally substituted with lower alkyl, lower perfluoroalkyl or phenyl are disclosed. These novel compounds are useful for treatment of symptoms associated with depression. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of depression and fatigue.
